PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
March 29, 2026British journal of surgery

SRS134 - Evaluating the impact of age on 21-gene recurrence score results—a systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

EKEoin KerinLMLuis Bouz MkabaahJCJack Collins

Discussion

Loading...

Member takes

Overview

Systematic review assesses recurrence score testing across age groups, implying the need for better guidelines.

Key Points

  • To evaluate the impact of age on the utilization and clinical benefit of recurrence score (RS) testing in breast cancer.
  • Conducted systematic review and meta-analysis according to PRISMA guidelines.
  • Included RCTs and cohort studies comparing RS testing across three age groups: <50, 50–69, and >70 years.
  • Analyzed RS uptake, score distribution, and subsequent chemotherapy use.
  • Elderly patients (>70 years) were significantly less likely to undergo RS testing than younger patients.
  • Elderly patients had higher rates of low-risk RS results compared to younger counterparts.
  • Elderly patients were less likely to receive chemotherapy based on high-risk RS results.

Cite This Study

Kerin et al. (2026) studied this question.

synapsesocial.com/papers/69c8c34bde0f0f753b39dfe4https://doi.org/10.1093/bjs/znag018.130
View Full Paper
Ask AI
Bookmark
Share